Weekly Sepsis Research Analysis
This week’s sepsis literature highlights rapid translational advances: an FDA‑approved antifungal (ciclopirox olamine) was repurposed as a direct NLRP3 inflammasome inhibitor with murine efficacy, revealing an immediately testable drug‑repurposing path; mechanistic work identified a TGFβ–PD‑L1 immune‑checkpoint in neutrophils that balances tissue protection and antimicrobial trafficking, offering a novel immunomodulatory target; and a multicenter randomized trial showed procalcitonin‑guided anti
Summary
This week’s sepsis literature highlights rapid translational advances: an FDA‑approved antifungal (ciclopirox olamine) was repurposed as a direct NLRP3 inflammasome inhibitor with murine efficacy, revealing an immediately testable drug‑repurposing path; mechanistic work identified a TGFβ–PD‑L1 immune‑checkpoint in neutrophils that balances tissue protection and antimicrobial trafficking, offering a novel immunomodulatory target; and a multicenter randomized trial showed procalcitonin‑guided antibiotic stopping safely shortens treatment in neonatal late‑onset sepsis, reinforcing biomarker‑driven stewardship.
Selected Articles
1. Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases.
Researchers identified the FDA‑approved antifungal ciclopirox olamine (CPX) as a selective NLRP3 inflammasome inhibitor that binds the NACHT domain (Y381), reduces ATPase activity, blocks oligomerization, and improved outcomes in murine sepsis models and ex vivo human cells.
Impact: Offers a concrete drug‑repurposing opportunity with defined molecular engagement of a central inflammatory driver in sepsis (NLRP3), accelerating the path to early‑phase trials compared with de novo drug discovery.
Clinical Implications: Prioritize PK/PD, safety and dose‑ranging studies for systemic CPX in sepsis, followed by early human trials—if translatable, NLRP3 inhibition could be an adjunct to blunt maladaptive inflammation in selected patients.
Key Findings
- CPX selectively blocks NLRP3 inflammasome activation (no effect on AIM2, NLRC4, Pyrin, NLRP1/6).
- CPX binds NACHT domain at Y381, reduces NLRP3 ATPase activity, and prevents oligomerization.
- Therapeutic CPX improved outcomes in murine sepsis models and showed activity ex vivo in human cells.
2. TGFβ-PDL1 signaling in neutrophils preserves lung barrier during hyperinflammation.
Mechanistic murine studies identify a TGFβ→PD‑L1 axis in neutrophils that restrains pathogenic hyperactivation during cytokine storm, promoting intravascular clustering that limits tissue infiltration and preserves lung barrier integrity; neutrophil‑specific PD‑L1 deletion shifts trafficking and augments tissue infiltration with tradeoffs for barrier injury.
Impact: Reveals a novel neutrophil immune‑checkpoint that mechanistically balances host defense and tissue protection—crucial for designing immunomodulatory therapies that avoid worsening barrier injury or impairing antimicrobial trafficking.
Clinical Implications: Translational priority should be given to validating the TGFβ–PD‑L1 axis in human sepsis tissues and to carefully exploring pharmacologic modulation (timing/dose) to optimize defense vs tissue protection in clinical trials.
Key Findings
- TGFβ signaling upregulates PD‑L1 on neutrophils and restrains hyperactivation during cytokine storm.
- PD‑L1 promotes intravascular neutrophil clustering and limits tissue infiltration, preserving lung barrier.
- Neutrophil‑specific PD‑L1 deletion reverses clustering, restores trafficking to infection foci, but increases tissue injury and spontaneous lung infection.
3. Procalcitonin-guided decision and antibiotic treatment duration in late onset sepsis of newborns: multicentre, randomised controlled trial (ProABIS).
In a 33‑center RCT (n=504), procalcitonin‑guided recommendations (PCT ≤0.5 µg/L measured every 48 h to suggest stopping) shortened median antibiotic duration from 10 to 8 days without increasing 28‑day mortality or recurrence, supporting safe biomarker‑based antibiotic stewardship in neonatal late‑onset sepsis.
Impact: Provides high‑level randomized evidence that a readily available biomarker can safely reduce antibiotic exposure in a vulnerable population—immediately relevant to guideline and stewardship updates.
Clinical Implications: Incorporate PCT measurement (threshold ≤0.5 µg/L, reassess every 48 h) into neonatal late‑onset sepsis protocols to safely shorten antibiotic courses where meningitis, shock, or deep infections are excluded; align stewardship and culture practices accordingly.
Key Findings
- Median antibiotic duration reduced from 10 to 8 days with PCT guidance (P<0.001).
- 28‑day mortality was non‑inferior (2.4% PCT vs 3.9% usual care) and recurrence rates were similar.
- Operational protocol: non‑binding stop recommendation when PCT ≤0.5 µg/L, measured every 48 hours.